Agent selectively targets malignant B cells in chronic leukemia, study shows
COLUMBUS, Ohio – A new experimental drug selectively kills the cancerous cells that cause chronic lymphocytic leukemia, according to a new study by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).
The study shows that the experimental agent PCI-32765 selectively kills the malignant B lymphocytes that cause chronic lymphocytic leukemia (CLL).
The researchers say the findings, published online in the journal Blood, are important because current CLL therapies ...



